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Objective: We undertook this study to determine whether changes in blood coagulability associated with peripheral
arterial occlusive disease are due to contact with the atherosclerotic arterial wall or passage through distal ischemic tissue.
Methods: Thirty patients with peripheral arterial occlusive disease undergoing angiography participated in the study.
Ankle-brachial pressure index was recorded before intervention. Blood samples taken from the aorta, common femoral
artery, and common femoral vein were analyzed at thromboelastography. Angiograms were scored for stenotic disease by
a radiologist blinded to the other results.
Results: When femoral artery samples were compared with aortic samples there was a decrease in reaction time (R; P <
.05), an increase in maximum amplitude (MA; P < .05), and an increase in coagulation index (CI; P < .002), indicating
an increase in coagulability as blood flowed down the iliac segment. These changes also correlated (R, r  0.442, P <
.05; MA, r  0.379, P < .05; CI, r  0.429, P < .05) with the severity of disease in the ipsilateral iliac segment.
Significant differences in R (P < .05), angle (P < .05), MA (P < .005), and CI (P < .001) between common femoral
arterial and venous samples confirmed that venous samples were more coagulable in this group of patients. This difference
in Thromboelastography parameters across the arteriovenous segment correlated inversely with the degree of ischemia
(represented by ankle-brachial pressure index; CI, r  0.427, P < .05; MA, r  0.370, P < .05) in the puncture
side limb.
Conclusion: Passage of blood down an atherosclerotic artery leads to an increase in coagulability proportional to the
degree of stenosis in that vessel. Passage of blood through ischemic tissue may also contribute to increased coagulability
in peripheral arterial occlusive disease. (J Vasc Surg 2004;39:1033-42.)Peripheral venous blood samples demonstrate a sys-
temic increase in coagulability in patients with peripheral
arterial occlusive disease (PAOD) affecting the legs.1-4
Fibrinogen5 and products of the coagulation cascade, in-
cluding thrombin-antithrombin complexes, prothrombin
F1 and F2,6 and D-dimers,7 indicating increased thrombin
synthesis and fibrinolysis, are consistently increased in
PAOD. Ischemic heart disease is associated with similar
changes.8-10
The mechanism responsible for these changes is not
clear. Potential causes of activation of the coagulation
cascade include contact between circulating blood and
atherosclerosis in the vessel wall, and passage of blood
through ischemic tissue. Circulating fibrinogen levels in
PAOD correlate inversely with mean ankle-brachial pres-
sure index (ABPI)11 and with angiographic scoring.12 The
degree of coagulation activation, indicated by systemic
levels of thrombin-antithrombin complex, increases with
the severity of disease at angiography or duplex scanning.11
Fibrinolytic activity, reflected in D-dimer levels, also corre-
lates inversely with mean ABPI12 and angiographic scor-
ing.11
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doi:10.1016/j.jvs.2003.12.039It is therefore clearly established that an ischemic limb
has associated increased clotting activity, but although
Lassila et al11 and Woodburn et al12 showed a correlation
between the level of activation and the extent of atheroscle-
rosis, the extent of atherosclerosis also correlates with the
degree of ischemia, and thus it is still not clear which drives
the increase in clotting activity. We have used thromboelas-
tography (TEG; Thromboelastograph Hemostasis Ana-
lyzer; Hemoscope Corp, Niles, Ill) to measure changes in
platelet function and the coagulation cascade across the
ischemic limb, then sought to determine whether the
changes in coagulability were caused by flow through an
atherosclerotic vessel or through ischemic tissue. TEG en-
ables measurement of the viscoelastic properties of a blood
clot, and thereby gives information about the combined
function of all factors involved in the process of clot forma-
tion and its subsequent dissolution (fibrinolysis). This is in
contrast to routinely available coagulation tests, which as-
sess only isolated stages of this process. TEG enables iden-
tification of functional abnormalities of factors involved in
coagulation, even if their concentration is in the normal
range, and it is a sensitive, specific, rapid method for assess-
ing coagulation.13 TEG has been used to detect activation
of coagulation in patients undergoing general surgical,14
abdominal aortic,15 and neurosurgical procedures,16 and
TEG-guided transfusion protocols reduce blood and blood
product usage in patients undergoing cardiac bypass pro-
cedures.17 TEG has been used in patients undergoing
abdominal aortic aneurysm repair, to identify postoperative
hypercoagulability, to monitor the adequacy of anticoagu-
lation (heparinization) during peripheral vascular recon-1033
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function in vascular disease.19
The goals of this study were to measure changes in
coagulability of blood as it circulates from the aorta
through an ischemic leg to the common femoral vein, with
TEG; to identify any relationship between changes in TEG
parameters and angiographic severity of atherosclerotic dis-
ease in the intervening vessels; and to identify any relation-
ship between changes in TEG parameters as blood flows
from common femoral artery to vein, and the degree of
ischemia in the limb.
MATERIAL AND METHODS
Subjects. Thirty sequential patients older than 40
years who were undergoing transfemoral angiography be-
cause of lower limb peripheral vascular disease via retro-
grade femoral puncture and who agreed to participate in
the study were recruited. Demographic data, coexistence of
other disease, and smoking habits were recorded. The
ABPI in both legs was measured, and that in the symptom-
atically less affected leg was used as a measure of the severity
of ischemia for the purposes of the study.
Fig 1. Thromboelastography values (mean) for blood sa
time (time to initial fibrin formation); K, dynamics o
cross-linking (clot strengthening); MA, maximum ampl
coagulation status); ABPI, ankle-brachial pressure indexAll patients underwent duplex scanning of the lower
limb veins bilaterally, to rule out deep vein thrombosis
(DVT) before angiography.
Exclusion criteria for participation in the study in-
cluded presence of DVT, liver impairment, known hyper-
coagulable state (excluding PAOD, ischemic heart disease,
and cerebrovascular disease), and any malignancy. Those
patients who were receiving warfarin because of cardiac
valve replacement stopped it 3 days before angiography and
were given heparin infusion until 4 hours before the inter-
vention. Patients receiving subcutaneous low-dose heparin
for DVT prophylaxis did not stop it before angiography.
Activated partial thromboplastin time (aPTT) and pro-
thrombin time (PT) were confirmed to be in the normal
range before angiography in all patients, but heparinase
cups were used in the TEG analysis in those who had
received heparin, because heparin can still affect this assay
even when aPTT and PT are normal.20 Patients receiving
warfarin because of atrial fibrillation discontinued it 3 days
before angiography, and were not given heparin. These
patients also had PT and aPTT in the normal range before
angiography was performed, and heparinase cups were not
obtained during transfemoral angiography. R, Reaction
formation; Angle, acceleration of fibrin buildup and
(ultimate clot strength); CI, coagulation index (overall
, transfemoral angiography.mples
f clot
itude
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TEG analysis of blood samples from 15 patients undergo-
ing aortic aneurysm repair or peripheral vascular recon-
struction procedures. The samples were taken from a radial
artery line before and 2 minutes after heparin (5000 IU)
administration via a central vein. We found no significant
differences (Mann-Whitney U test) in TEG parameters
between samples analyzed before and after heparin admin-
istration with heparinase21-coated cups, confirming com-
plete reversal of exogenous heparin.
Blood sampling and analysis. Blood samples were
obtained from the common femoral vein (sample V) on the
same side as the intended arterial puncture, via separate
percutaneous puncture, after infiltration of the subcutane-
ous tissue with local anesthetic (lignocaine 1%).
The radiology protocol dictated that this puncture be
on the side of the less symptomatic leg. A sample was then
taken from the ipsilateral common femoral artery (sample
A) via separate arterial puncture with a size 19 needle,
before insertion of a guide wire, followed by angiography
sheath insertion (Seldinger method22) and collection of
aortic blood samples from the abdominal aorta (sample Ao)
via the catheter before injection of contrast material (Fig 1).
Citrated tubes were used for storage of blood samples
before analysis.23,24 TEG was used to analyze the coagula-
tion state of each blood sample (Fig 2), and this yielded five
parameters: R, K, angle (&alpha), MA, and CI (Fig 2).
Fig 2. Coagulation state of each blood sample. R, React
formation; Angle, acceleration of fibrin buildup and cr
(ultimate clot strength); CI, coagulation index (overall co
LY60, percent lysis at 60 minutes after MA; G, clot firmn
current amplitude.R is the latent period between placing the sample in the
analyzer and the initial fibrin formation, and it correlates
with platelet activity. K time is a measure of the period from
the beginning of clot formation until the amplitude of the
TEG trace reaches 20 mm, and represents the dynamics of
clot formation. Angle, or alpha () is the angle between the
horizontal line through the center of the TEG tracing and
the line tangential to the developing “body” of the TEG
tracing. The alpha angle represents the acceleration of
fibrin buildup and cross-linking (clot strengthening). MA,
or maximum amplitude, is a direct function of the maxi-
mum dynamic properties of fibrin and platelet bonding via
glycoprotein IIb and IIIa receptors; it represents the ulti-
mate strength of the fibrin clot, and depends on the num-
ber and function of platelets and their interaction with
fibrin. CI, or coagulation index,25 describes the patient’s
overall coagulation status, and is derived from R, K, MA,
and angle () of blood tracings:
CI  0.245R 0.0184K 0.1655MA-0.0241
 5.0220
TEG analyses of samples were carried out after storage
in citrate for 1 to 8 hours. In a previous study of TEG assay
variability, 15 citrated peripheral venous blood samples
collected from patients with vascular disease were analyzed
after 1 hour of storage. Each sample was analyzed, divided
me (time to initial fibrin formation); K, dynamics of clot
nking (clot strengthening); MA, maximum amplitude
tion status); LY30, percent lysis at 30 minutes after MA;
s shear elastic modulus; EPL, estimated percent lysis; A,ion ti
oss-li
agula
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intra-assay variability was excellent (P  NS), and the
reliability coefficients () were greater than 0.9 for all
parameters studied (R, K, angle, MA, CI). Samples from
any patient receiving heparin before angiography were an-
alyzed with a heparinase21-coated cup.
Assessment of disease severity. Arteriographic find-
ings were interpreted by a vascular radiologist blinded to
the TEG results.
Atherosclerotic disease in the aortoiliac segment on the
same side as the arterial puncture was reported as maximum
percentage (%) diameter stenosis and graded as less than
50% (minimal), 50% to 70% (moderate), and greater than
70% (severe). Infrainguinal disease was graded in four
segments (superficial femoral artery, popliteal artery, trifur-
cation, crural vessels) as less than 50% or 50% or greater
stenosis at any point. A score of 0 for less than 50% and 1 for
50% or greater was given, and the total score for infraingui-
nal disease was calculated for the puncture side limb in each
patient.
Statistical analysis. TEG and patient group data were
analyzed with the Wilcoxon signed rank test, Spearman
correlation, and descriptive analyses (SPSS version 11.00;
SPSS, Chicago, Ill), including mean and standard deviation
values for the TEG parameters and frequency of distribu-
Table I. Clinical and angiographic data for study group
Parameter
No. of patients
(N  30)
Risk factors
Antihypertensive therapy 26
Diabetes 11
Smoking (current) 16
Hyperlipidemia 19
Previous acute myocardial
infarction
7
Previous cerebrovascular accident 4
Previous deep venous thrombosis 2
Previous peripheral vascular surgery 13
Aortic aneurysmal disease 4
Antiplatelet therapy 12
Anticoagulation therapy (warfarin
stopped 3 days before
angiography)
4
Symptoms
Short-distance claudication 7
Rest pain 9
Tissue loss 14
Ankle-brachial pressure index
Puncture side limb (mean  SD) 0.74  0.15
Opposite, more symptomatic, limb
(mean  SD)
0.50  0.15
Angiographic severity of Iliac disease
in puncture side limb (%)
Stenosis 70% (severe) 8
Stenosis 50%-70% (moderate) 10
Stenosis 50% (minimal) 12
Total angiographic score for
infralinguinal disease
Median 2.00
Range 3.00tion of vascular risk factors. The Mann-Whitney U test was
used for comparison of TEG parameters between groups.
The Ethics Committee of Oxford Radcliffe Hospitals
NHS Trust approved the study.
RESULTS
The 30 study patients (21 men, nine women; median
age, 72  9.6 years) underwent transfemoral angiography
for a range of ischemic symptoms, including intermittent
claudication (n 8), rest pain (n 9), and ischemic tissue
loss (n 13). Two patients were receiving warfarin because
of heart valve replacement, and three were receiving low-
dose subcutaneous heparin for DVT prophylaxis. Another
two patients receiving warfarin because of atrial fibrillation
stopped it before angiography. Further details are given in
Table I.
Fifty-five percent of common femoral arterial punc-
tures were on the left side. Angiographic scoring for disease
severity is given in Table I.
When comparing common femoral artery samples with
aortic samples (Table II), there was a decrease in R (time to
onset of clotting, reflecting platelet activity; P .05; Fig 3),
an increase in MA (clot strength; P  .05; Fig 4), and an
increase in CI (coagulation index; P  .002; Fig 5), con-
sistent with an increase in coagulability due to both platelet
activation and increased thrombin generation as blood
flowed down the iliac arteries. These changes in TEG
parameters also correlated with the severity of atheroscle-
rotic disease in the ipsilateral aortoiliac segment (R, r 
0.442, P .05; MA, r 0.379, P .05; CI, r 0.429,
P  .05).
TEG parameters showed significant differences in R (P
 .05), angle (measure of clot development; P .05), MA
(P  .005), and CI (P  .001) between common femoral
arterial and venous samples, confirming that venous sam-
ples were more coagulable in this group of patients, again
due to increased platelet activation and thrombin produc-
tion (Table III). This difference in coagulation between the
arterial and venous ends of the circulation in the puncture
side limb correlated inversely with degree of ischemia
(ABPI) on that side (CI vs ABPI, r  0.427, P  .05;
MA vs ABPI, r  0.370, P  .05; Figs 6 and 7). The
change in MA across the limb circulation also correlated
with the angiographic score for infrainguinal disease (MA,
r  0.459, P  .05; Fig 8), but none of the other TEG
parameters did so.
Twelve patients were taking regular aspirin, and had
prolongation of R time in samples taken from the aorta (Ao
R; P  .05) and prolongation of K values in samples taken
from the common femoral artery (P .05), compared with
the 18 patients not taking aspirin.
Neither gender nor hyperlipidemia were associated
with significant differences in TEG parameters. We found a
significant decrease in K value in venous samples taken from
the common femoral vein (P .05), but no other changes
in TEG parameters in those who were smokers compared
with nonsmokers and ex-smokers.
JOURNAL OF VASCULAR SURGERY
Volume 39, Number 5 Shankar et al 1037Patients with diabetes demonstrated significantly re-
duced K time (rapidity of clot strengthening; P  .05),
increased angle (acceleration of fibrin buildup; P  .05),
and MA (ultimate clot strength; P  .05).
Fig 3. Severity of iliac disease
Fig 4. Severity of iliac disease andWe also found a significant decrease in R (P .05) and
K (P  .05) and increase in angle (P  .05) and CI (P 
.05) in blood samples taken from the common femoral vein
in patients with a history of DVT (n  2), compared with
change in reaction (R) time.
ge in maximum amplitude (MA).andchan
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a history of acute myocardial infarction, cerebrovascular
accident, and peripheral vascular surgery did not differ from
those in patients without such history.
DISCUSSION
Our study confirms that blood becomes more coagula-
ble as it traverses the ischemic limb. Platelet activation, as
well as increased thrombin production, takes place within
the limb. Blood coagulability increases as it flows down an
atherosclerotic iliac artery, and the magnitude of that
change is related to the severity of stenosis. Ischemia is
unlikely to have a role here, and it is probable that the
changes in blood coagulability are caused by the presence
Table II. Correlation between changes in thromboelastog
and extent of iliac stenosis
Parameter
Mean difference between aortic
samples (Mean/CI
Mean  SD
R 0.44  3.1
K 0.08  1.67
Angle 2.08  12.3
MA 3.1  9.97
CI 0.75  1.42
R, Reaction time (time to initial fibrin formation); K, dynamics of clot form
MA, maximum amplitude (ultimate clot strength); CI, coagulation index (
Fig 5. Severity of iliac disease anof atherosclerotic disease. This may be due to interaction
with atherosclerotic plaque, but in the carotid and coronary
arteries, where this has been extensively studied, enhanced
coagulation is usually associated with “unstable plaque”
and ulceration. We recorded no details of plaque ulceration
or measures of plaque stability, but unstable plaque is
usually associated with acute symptoms rather than the
relatively stable chronic ischemia seen in our patients. An-
other possible cause of coagulation activation in the iliac
arteries might be the increased shear stress26 associated
with localized stenosis. This induces platelet aggregation in
both acute coronary syndromes27 and chronic coronary
artery disease.28 It is possible that other steps in coagulation
are also activated under such circumstances. The third
ic parameters between aorta and common femoral artery
femoral
Correlation with Iliac disease
confidence
nterval r P
.6, 0.72 0.443 .014
.54, 0.7 0.151 .151
.5, 6.6 0.218 .248
.62, 6.8 0.379 .039
.22, 1.2 0.429 .018
Angle, acceleration of fibrin buildup and cross-linking (clot strengthening);
coagulation status).
ange in coagulation index (CI).raph
and
)
95%
i
1
0
2
0
0
ation;
overalld ch
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plaque promotes coagulation, although there is no direct
evidence for this in the literature.
Changes recorded as blood flows through the ischemic
limb are more complex. It is presumed that the same
mechanisms that induce a change in coagulability in the
iliac segment also have a role in changes within the limb.
Sobel et al29 demonstrated increased thrombin gener-
ation within the ischemic limb by measuring fibrinopeptide
A levels, which were consistently higher in venous samples
than in the arterial inflow to an ischemic limb. These same
authors found no increase in -thromboglobulin, and con-
cluded that there was no activation of platelets across the
ischemic leg, although other studies have found systemic
evidence of platelet activation in such limbs.30
We attempted to measure the extent of atherosclerotic
disease in the infrainguinal vessels with a crude angio-
Table III. Correlation between changes in thromboelasto
and ABPI
Parameter
Mean difference across A-V s
Mean  SD
R 0.91  0.43
K 0.30  0.15
Angle 3.53  1.49
MA 3.81  1.04
CI 0.76  0.19
ABPI, Ankle-brachial pressure index; A-V, arteriovenous; R, reaction time (t
of fibrin buildup and cross-linking (clot strengthening); MA, maximum amp
Fig 6. Correlation between change in coagulationgraphic score, but arteries that are heavily diseased are likely
to cause diversion of flow into disease-free collateral vessels;
indeed, blood will never be exposed to the most heavily
diseased (occluded) arteries. We did show a correlation
between the increase in coagulability across a limb and the
extent of ischemia, as measured with ABPI on that side.
Thus flow through ischemic tissue may promote coagula-
tion, but we cannot exclude the possibility that this rela-
tionship arises through the close association between the
severity of ischemia and the extent of atherosclerotic disease
past which the blood must flow to the distal limb. The
changes in coagulability could all be due to exposure to
atherosclerotic disease.
We have shown that arterial blood entering the isch-
emic leg is significantly less coagulable than that leaving it.
Somehow the degree of coagulation activation is reduced
before blood returns to the leg. The blood supply to even
ic parameters between common femoral artery and vein,
nt Correlation with ABPI
95%
fidence
terval r P
, 0.02 0.370 .074
2, 0.01 0.129 .496
7, 6.5 0.209 .268
, 5.9 0.370 .044
6, 1.16 0.427 .018
initial fibrin formation); K, dynamics of clot formation; Angle, acceleration
(ultimate clot strength); CI, coagulation index (overall coagulation status).
x (CI) and ankle-brachial pressure index (ABPI).graph
egme
Con
in
1.7
.6
0.4
1.6
0.3
ime to
litudeinde
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less than 10% of cardiac output, and thus is subject to
dilution by blood returning to the heart from elsewhere in
the body. In addition, activated clotting factors are re-
moved by the reticuloendotheial system, in particular the
Fig 7. Correlation between change in maximum ampli
ischemic limb.
Fig 8. Correlation between change in maximum amplit
infrainguinal atherosclerotic disease. A-V, arteriovenousliver.32 Thus blood returning to the ischemic limb has
much lower coagulation activity than blood that left it.
We used ABPI as a measure of ischemia rather than as a
measure of atherosclerotic disease in the limb, because it
reflects the perfusion pressure at ankle level and thus relates
(MA) and ankle-brachial pressure index (ABPI) across
MA) across ischemic limb and angiographic severity oftudeude (
.
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eral vessels as well as through stenosed arteries, and is
therefore not a measure simply of atherosclerotic disease.
We could have used symptoms as a measure of ischemia (eg,
asymptomatic vs claudication vs rest pain), but because we
were investigating the less symptomatic leg, any symptoms
of claudication could have been masked by more severe
disability in the other leg.
We used TEG to assess coagulation, because its sensi-
tivity and specificity compare well with routine coagulation
tests33,34 and it provides a measure of the overall coagula-
tion status of a given blood sample rather than of individual
clotting factors in isolation.35 TEG analysis of citrated
samples is more sensitive in the detection of procoagulant
alterations than other coagulation tests are,14 and is there-
fore ideal for assessment of coagulation in patients with
PAOD. Patients with peripheral vascular disease exhibit
increased aggregation of platelets in baseline measurements
when studied with aggregometry,36 and this has been
shown to increase further during and immediately after
peripheral vascular surgery despite preprocedure ingestion
of aspirin and administration of heparin during the proce-
dure. The TEG method has the potential to unmask hyper-
coagulability in these patients, and can enable identification
of those patients at risk for thrombotic events after vascular
surgery.
Aspirin ingestion in our patients (n 12) was reflected
in prolongation of R time in samples taken from the aorta,
and K values of samples taken from the common femoral
artery. Previous studies in subjects taking aspirin have failed
to detect an effect of aspirin. These studies were performed
in healthy control subjects, with blood samples taken from
a peripheral vein after ingestion of aspirin in doses up to
650 mg/d over 10 days. Our study involved subjects in
whom platelet activation already exists,1,37 and it is perhaps
not surprising that the results differ.
Patients with PAOD have relatively high mortality from
cardiovascular and cerebrovascular disease. A significant
part of that mortality relates to thrombosis in critical ves-
sels, which may be promoted by hypercoagulability of the
systemic circulation.
We have shown that atherosclerotic disease in the leg is
a potential promoter of coagulation. We do not know
whether the presence of ischemic tissue in the leg also
contributes. Our current approach to treatment of the
ischemic leg is to reverse ischemic changes or ablate isch-
emic tissue; we do not remove the atherosclerotic disease.
On the other hand, advances in drug therapy, in particular
cholesterol-lowering drugs, have the potential to reduce
the size of atherosclerotic plaque. We have shown that the
mere presence of such disease is sufficient to enhance
coagulation, but we do not yet know whether the persis-
tence of ischemic tissue is likely to prejudice patient survival
as a result of its systemic effect.
CONCLUSION
We have found that blood increases in platelet and
coagulation factor activity as it flows down the iliac vessel inproportion to the extent of iliac atherosclerotic disease. We
have also shown that blood circulating through an ischemic
limb increases in coagulability. Part of the change is prob-
ably due to contact with atherosclerotic arteries, but some
of the change may be due to flow through ischemic tissue.
We thank Dr R. Weatherall, Medical Statistician, at
ICRF/NHS Centre for Statistics in Medicine, Institute of
Health Sciences, Oxford, for valuable advice regarding the
statistical methods used in this study.
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